Delirium, an acute disorder of attention and cognition, is a common, serious, costly, underrecognized and often fatal condition for seniors. Its diagnosis requires a formal cognitive assessment and history of acute onset of symptoms. Given its typically complex multifactorial etiology, multicomponent nonpharmacologic risk factor approaches have proven to be the most effective strategy for prevention. To date, there is no convincing evidence that pharmacologic prevention or treatment is effective. Drug reduction for sedation and analgesia combined with nonpharmacologic approaches are recommended. Delirium may provide a window to elucidate brain pathophysiology, serving both as a marker of brain vulnerability with decreased reserve and a potential mechanism for permanent cognitive damage. As a potent patient safety indicator, delirium provides a target for system-wide process improvements. Public health priorities will include improvements in coding and reimbursement, improved research funding, and widespread education for clinicians and the public about the importance of delirium.
Introduction
Despite first being described over 2500 years ago, delirium remains frequently unrecognized and poorly understood. Delirium, an acute decline in cognitive functioning, is a common, serious, and often fatal problem affecting up to 50% of hospitalized seniors, and costing over $164 billion holds substantial public health relevance as a target for interventions to prevent its associated burden of downstream complications and costs. 6 Accordingly, delirium is now included on the patient safety agenda, 7 and has been increasingly targeted as an indicator of healthcare quality for seniors. 8, 9 Delirium can be thought of as "acute brain failure," a multifactorial syndrome analogous to acute heart failure and may provide a novel approach to elucidate brain functioning and pathophysiology. With its acute onset in response to noxious insults, such as major surgery or sepsis, delirium may help to shed light on cognitive reserve; that is, the brain's resilience to withstand external factors. 10 In this context, delirium may serve as a marker of the vulnerable brain with diminished reserve capacity. Recent evidence further suggests that the trajectory of "normal" cognitive aging may not be a smooth linear decline, but rather a series of punctuated declines and recoveries in the face of delirium and major medical insults. 11, 12 Finally, in addition to serving as a marker of the vulnerable brain, accumulating evidence (see "Current
Controversies" section below) suggests that delirium itself may lead to permanent cognitive decline and dementia in some patients.
The purpose of this report is to provide a state-of-the-art review of the syndrome of delirium to guide clinical practice and to elucidate important areas for future research.
[Panel] Search Strategy and Selection Criteria
Articles for this Review were identified by comprehensive searches of Medline, PubMed and reference lists from relevant original articles and systematic reviews (see Appendix Table 1) using the search terms: "delirium", "acute confusion", and "organic brain syndrome". Original articles published in English between 1990 and 2012 were included. To provide an overview of the areas of epidemiology, etiology, nonpharmacologic and pharmacologic management, reviews
were conducted from 2004-2012 to update a previous comprehensive review; 13 with the exceptions of validated risk prediction models and nonpharmacologic studies, where we expanded our search to include original articles published between 1990 and 2012. All data presented are taken from those of the original article; no meta-analysis was performed. In all non-ICU settings, the study populations included in the selected articles were generally age 65 years and older. For epidemiologic studies, we required a sample size of ≥ 100; prospective sampling framework; satisfaction of the STROBE criteria for setting, participants, measurement and statistical methods; and use of a validated delirium instrument. The pathophysiology search used the same search terms with the addition of "etiology", "pathophysiology", "physiopathology", or "pathogenesis". For nonpharmacologic and pharmacologic prevention and treatment studies, we required a sample size ≥ 25 in each study arm; prospective sampling framework; use of a validated delirium instrument; and a modified Jadad quality score of ≥ 4
(range 0-6) that included the following components: randomization or balanced allocation (1 point); appropriate description of randomization or balanced allocation (1 point); blinding (1 point); double blinding required for pharmacologic studies); appropriate description of blinding (1 point); description of dropouts/withdrawals (1 point); and N ≥100 (1 point). Two reviewers rated each article and reached consensus on all ratings. Since the goal of this manuscript was to provide a comprehensive review of primary articles, systematic reviews and meta-analyses were not routinely included; however, all of their reference lists were checked to insure the comprehensive inclusion of primary articles in our review process (Appendix Table 1 ).
Epidemiology
Based on a systematic literature review from 2004-2012, articles on incidence and outcomes of delirium were selected by the following criteria: sample size of 100 or more; prospective sampling framework; satisfaction of STROBE criteria; 14 and use of a validated delirium instrument. The timeframe for this review was chosen to update a previous comprehensive review. 13 An additional inclusion criterion for incidence studies was serial delirium assessments at no more than 3-day intervals by trained research staff or clinicians. Table 1 presents the prevalence rates (present on admission) and incidence rates (new onset) of delirium across different patient populations as described in 35 selected studies (See Appendix Table 4 for reference citations of all articles); the sum of both prevalence and incidence yields the overall occurrence rates in each setting. The highest incidence rates were observed in the intensive care unit, postoperative, and palliative care settings. Since many of these studies excluded patients with cognitive impairment or dementia at baseline, these rates likely represent underestimates of true incidence rates. In general medical and geriatric wards, the prevalence of delirium (present on admission) of 18-35% must be added to the incidence rates to yield the overall occurrence rates of delirium in these populations of 29-64% ( Table 1) . The prevalence of delirium in the community setting is relatively low (1-2%), but its onset usually brings the patient to emergency care. On presentation to the emergency department, delirium is present in 8-17% of all seniors and 40% of nursing home residents.
Adverse outcomes associated with delirium, drawn from selected studies that included adjustment for confounders, are presented in Table 1 . Delirium is consistently associated with an increased mortality rate across all nonsurgical patient populations, including general medical, geriatric, intensive care unit (ICU), stroke, dementia, nursing home, and emergency department.
Patients who develop delirium in the ICU are at 2-4 fold increased risk of death both in and out of the hospital; [15] [16] [17] [18] those who develop delirium on general medical or geriatric wards are at 1.5-fold increased risk for death in the year following hospitalization; [19] [20] [21] and patients with delirium in the emergency department have an approximately 70% increased risk of death during the first six months after the visit. 22 Cognitive impairment is common among surgical patients who develop delirium, with impairments lasting up to one year postoperatively; 12, 23, 24 and physical function is impaired for 30 days or more after discharge among surgical and non-surgical patients who develop delirium. 20, 25, 26 Delirium at admission to post-acute care is associated with a five-fold increased risk of six-month mortality. 27 Among older patients with dementia, delirium is associated with increased rates of cognitive decline, [28] [29] [30] institutionalization, 29 Table 2 ]. Over 24 delirium instruments have been used in published studies. 35, 36 The most widely used instrument for identification of delirium is the Confusion Assessment Method (CAM) [Appendix Table 3] , 6, 31, 36, 37 validated in high quality studies including over 1000 patients with sensitivity of 94%, specificity of 89%, and high interrater reliability. Cognitive testing and training are recommended for optimal use of the CAM.
The CAM, which has been used in over 4,000 published studies to date and translated into at least 12 languages, has been adapted for use in the ICU, 38 emergency department, 39 and nursing home, where it is now included as part of the Minimum Data Set, 40 a standardized comprehensive assessment of all residents in U.S. long-term care facilities. Behavioral checklists for delirium symptoms, such as DOS, 41 NuDESC, 42 and NEECHAM, 43 are used particularly in nursing-based studies. For measuring delirium severity, the most widely used tools include the Delirium Rating Scale (DRS and DRS-98) 44, 45 and Memorial Delirium Assessment Scale (MDAS). 46 Summation of CAM items has been used as a severity indicator. 4, 47, 48 A validated chart review method for identification of delirium has been developed for retrospective identification, 49 but its sensitivity is more limited. The Family Confusion Assessment Method (FAM-CAM) has been developed to identify delirium symptoms from reports of family and informal caregivers, which holds promise to assist with early recognition of delirium. 50 
Etiology
While a single factor may lead to delirium, more commonly delirium is multifactorial in older persons. The multifactorial model for the etiology of delirium has been well-validated and widely accepted. 51 The development of delirium involves the complex inter-relationship between a vulnerable patient with multiple predisposing factors and exposure to noxious insults or precipitating factors (Figure 1) . Thus, in patients who are highly vulnerable to delirium, such as those with underlying dementia and multimorbidity, a relatively benign insult--such as a single dose of sleeping medication--may be enough to precipitate delirium. Conversely, in a young healthy patient, delirium will develop only after exposure to a series of noxious insults, such as general anesthesia, major surgery, multiple psychoactive medications, ICU stay, and sleep deprivation. Clinically, the implications of this multifactorial etiology are that addressing a single risk factor is unlikely to resolve the delirium, and that multicomponent approaches will be most effective for both prevention and treatment.
To date, many risk factors for delirium have been identified. 13, 52 Predictive models for delirium are useful to identify high risk patients for proactive implementation of preventive strategies, for identifying patients who need closer monitoring, for identifying vulnerability factors for intervention, for prognostic decision-making, and for determining clinical trial eligibility. The ability to stratify risk can assist physicians in explaining risks to patients and families, and can help families to better understand the recovery process and potential outcomes.
Pathophysiology
Given the complex multifactorial etiology of delirium, each individual episode of delirium is likely to have a unique set of component contributors, with each set representing a discrete yet sufficient causal mechanism that may differ with each episode. Thus, it is likely that the quest for a single cause or mechanism for delirium--the "final common pathway"--will remain unanswered. Rather, accumulating evidence suggests that several different sets of interacting biological factors result in disruption of large-scale neuronal networks in the brain, leading to acute cognitive dysfunction. 53 Some of the leading hypothesized mechanisms contributing to delirium appear in Table 3 including neurotransmitters, inflammation, physiologic stressors, metabolic derangements, electrolyte disorders, and genetic factors. Many biological factors may interfere directly with neurotransmission and/or cellular metabolism, 54 including drugs, 55 hypercortisolism, 56 electrolyte disturbances, 57 hypoxia, 58 or impaired glucose oxidation. 59 The list of potential neurotransmitters involved in delirium is long, 60 but a relative cholinergic deficiency and/or dopamine excess are the most commonly inferred, 61, 62 correlating with the adverse effects of anticholinergic or dopaminergic drugs. 63 Other causal mechanisms interfere with neurotransmission more indirectly. For instance, the systemic inflammatory response seen in sepsis may result in a cascade of local (brain) neuroinflammation triggered by inflammatory cytokines, leading to endothelial activation, impaired blood flow, and neuronal apoptosis. Neuroinflammation can lead to microglial overactivation, resulting in a neurotoxic response with further neuronal injury. 64 Peripheral inflammation can also activate the central nervous system by several routes, including vagal afferents, circulating pro-inflammatory cytokines, 65 endothelial activation with disruption of the blood-brain barrier, 66 and microglial activation. 67 The distinction between local and distant pathologies may be artificial, however, since the different inflammatory factors and neurotransmitters are closely intertwined. 68 Advanced neuroimaging techniques may shed additional light on pathophysiology. Local and distant factors together account for overall and regional perfusion abnormalities observed in the delirious brain. 69, 70 Total cerebral and regional perfusion are decreased with impaired cardiac output 71 and with loss of cerebral autoregulation in the damaged brain; 72 both mechanisms may be at play during sepsis. 73 In addition, rapidly evolving functional imaging techniques may provide a powerful means to help differentiate preexisting changes and more newly acquired structural damage related to delirium. 74 Although delirium can occur at any age, the young and the old carry the highest risks. In the young, neuronal networks that are underdeveloped and less complex might be more easily perturbed. 75 In the old, gradual accumulation of permanent damage to neurons, dendrites, receptors, and microglia, 76 as well as the impact of cerebrovascular disease or head trauma, may render the old, particularly those with underlying cognitive impairment, more susceptible to delirium when biologically stressed. 77 Depending on the underlying causal mechanism, patients may overcome a delirious state without any residual effects or, alternatively, develop permanent neurological sequelae. 78, 79 Understanding the pathophysiologic basis for the stressors and the substrates leading to permanent damage from delirium will advance the concept of cognitive reserve, opening new avenues for risk stratification and therapeutic approaches. 80 Evaluation and Work-Up
The most important step in the evaluation is to establish the diagnosis of delirium by obtaining a history from an informed observer (e.g., family member, caregiver, or staff member) and by performing a brief cognitive assessment. To differentiate delirium from dementia, obtaining the history is critical to establish the patient's baseline, determine the acuity of mental status change and fluctuations typical of delirium, and to search for etiologic clues. Brief cognitive screening should be conducted with formal cognitive screening tests, such as the Short Portable Mental Status Questionnaire, 81 the Mini-Cog, 82 or the Montreal Cognitive Assessment. 83 If time is extremely limited, then assessment of orientation along with an attention task, such as naming days of the week (allow 0 errors) or months of the year (allow 1 error) backwards, serial 7's (allow 1 error on 5 subtractions), or reciting digit spans backwards (normal: ≥ 3 digits backwards) can provide a basic screening. With this cognitive testing, fulfillment of screening criteria for delirium can be determined.
Given the high rates of adverse outcomes and mortality, any suspected or uncertain case (including those with lethargy or who are unable to complete an interview) should be treated as delirium until proven otherwise. The initial management focuses on three simultaneous priorities: (1) maintaining patient safety; (2) searching for the causes; and (3) managing delirium symptoms. For maintaining patient safety, efforts should focus on protecting the airway and preventing aspiration; maintaining hydration and nutrition; preventing skin breakdown;
providing safe mobility while preventing falls; and avoiding restraints and bed alarms which have been shown to increase risk and persistence of delirium, and of injury. Table 4 outlines the suggested work-up and initial management for delirium. Several fundamental points in the evaluation of delirium are worthy of special emphasis. First, because delirium can be the harbinger of a medical emergency, every patient presenting with delirium should be screened for acute physiologic disturbance such as hypoxemia, low blood glucose, and high arterial carbon dioxide. Another challenging aspect is the occult or atypical presentation of disease in older persons; for instance, an octogenarian with myocardial infarction presents more often as delirium than with classic symptoms of chest pain or shortness of breath. Thus, a nonspecific complaint from a family member that the patient "is just not him/herself" should never be taken lightly. Another important principle is that the diagnostic evaluation (e.g., laboratory testing, neuroimaging) must be targeted based on the history and physical examination; an untargeted battery of testing is likely to be low-yield. 86 The electroencephalogram (EEG) has limited sensitivity and specificity in diagnosis of delirium.
84, 85
However, delirium does result in a characteristic pattern of diffuse slowing with increased theta and delta activity and poor organization of background rhythm that correlates with severity of delirium. EEG can be particularly useful to differentiate organic etiologies from functional or psychiatric disorders in difficult-to-assess patients, to evaluate deteriorating mental status in patients with dementia, and to identify occult seizures (e.g., nonconvulsive status epilepticus or atypical complex partial seizures). 87, 88 Quantitative and spectral EEG may further assist in evaluation of delirium, but their performance characteristics need further investigation. and may be a useful adjunct to a nonpharmacologic sleep protocol. 93 The Delirium Room 105 is
another intriguing concept to provide specialized management for delirium patients, but has not yet been evaluated in a controlled trial. Unfortunately, many of the nonpharmacologic studies to date have been hampered by methodologic limitations, such as lack of prospective balanced allocation to study groups, lack of a comparison group, or unblinded outcome assessment.
Pharmacologic Prevention and Treatment
Pharmacologic approaches for prevention and treatment of delirium are summarized in Table 6 (see references for included articles in Appendix Table 9 ). This table presents 16 studies which included at least 25 patients each in intervention and control groups, applied a prospective sampling framework, used a validated delirium assessment, and achieved a modified Jadad score 94 of at least 4 points. While these clinical trials have used a variety of pharmacologic approaches, at present there is no convincing, reproducible evidence that any of these treatments are clearly effective for either prevention or treatment of delirium. In six of these trials, there was no difference in delirium rates. In eight of these trials, the target treatment did reduce delirium rates, but the observed reduction either had no impact on clinical outcomes (such as intensive care unit (ICU), hospital length of stay, hospital complications, or mortality), or clinical outcomes were not measured. In two trials, the treatment resulted in potentially worse outcomes:
olanzapine reduced incidence, but resulted in greater duration and severity of delirium (without reported clinical outcomes); and rivastigmine resulted in higher delirium duration and mortality.
Notably, all of these trials used different approaches to the assessment of delirium and evaluated diverse patient populations; thus, generalizing findings is difficult. Given the preponderance of evidence, however, pharmacologic approaches to prevention and treatment are not recommended at this time. 6, 106 Current Controversies
While research in the field of delirium has been booming with the number of research articles on delirium increasing from fewer than 30 per year in 1980 to over 400 per year in 2011, many key aspects of delirium remain poorly understood. While some biomarkers associated with delirium have been identified, the fundamental pathophysiologic basis of delirium remains obscure. Thus, important knowledge gaps will need to be addressed to move the field ahead.
Does delirium lead to dementia?
A major area of controversy is whether delirium is simply a marker of vulnerability to dementia, or whether delirium itself leads to dementia. Ultimately, it is likely that both hypotheses are true. There is little doubt that occurrence of an episode of delirium can signal vulnerability of the brain with decreased cognitive reserve and increased risk for future dementia. In some cases, delirium may bring previously unrecognized cognitive impairment to medical attention. Delirium and dementia commonly coexist, with dementia being a leading risk factor for delirium, i.e., increasing delirium risk by 2-5 fold on hospital admission ( Table 2) . Moreover, the evidence for delirium leading to permanent cognitive impairment and dementia is increasing, ranging from epidemiologic evidence to tissue culture and animal models. A recent meta-analysis 107 involving two studies with 241 total patients demonstrated that delirium was associated with an increased rate of incident dementia, (adjusted relative risk, RR, 5.7, 95% confidence interval, CI, 1.3-24.0). In a sample of 225 cardiac surgery patients, delirium resulted in a severe punctuated decline in cognitive functioning, followed by recovery over 6-12 months in most patients; however, a substantial proportion, particularly those with prolonged delirium, never return to baseline. 12 In 263 patients with Alzheimer's disease, delirium resulted in a fundamental alteration in the trajectory of cognitive decline with a 2-fold acceleration in rate of decline over the year following hospitalization, and accelerated decline persisting over the 5-year follow-up period. 30 Additional evidence supports a more direct role for delirium in dementia. An important study with neuropathological confirmation 78 demonstrated that in 553 individuals who were 85 years and older at baseline, delirium increased the risk of incident dementia (odds ratio 8.7, 95% CI 2.1-35). In patients without delirium, Alzheimer's pathology was significantly associated with dementia, whereas no such relationship was seen in those with delirium, raising the possibility of alternative pathologic mechanisms for dementia following delirium. This study was limited, however, by a high rate of missing follow-up observations. Previous studies in animal models and human neuronal cell culture have demonstrated that exposure to inhalational anesthetics may induce neurotoxicity, including apoptosis, caspase activation, A-beta oligomerization and accumulation, neuroinflammation, and mitochondrial dysfunction. 108, 109 Preliminary results in humans 110 suggest some inhalational anesthetic agents (e.g., isoflurane) may be more neurotoxic than others. Important recent work involving animal models of delirium have demonstrated that in vulnerable animals, systemic inflammatory insults can cause punctuated cognitive decline typical of delirium, followed by acceleration in disease progression typical of dementia. 111 Furthermore, a single dose of lipopolysaccharide, inducing an inflammatory insult comparable to a moderate infection in humans, has been shown to induce neuronal death, microglial activation, decreased regional blood flow, and loss of cholinergic activation. 112 This accumulating evidence, therefore, lends strong support for the impact of delirium itself contributing to and/or being a mediator of permanent cognitive impairment. Future human studies with careful baseline characterization of cognitive function, control for confounding factors, and long-term follow-up, including neuropsychological testing and neuroimaging, will be helpful to address this important area.
Is delirium primarily a disorder of cognition or arousal?
Historically, delirium was first categorized as a "mental status" problem, a disorder of arousal with varying degrees of obtundation. However, with advances in the field and more sophisticated observation, delirium is now considered to be primarily a disorder of cognition with attention and global cognitive impairments as the key features, rather than a primary disorder of arousal alone. 31, 112 This distinction is important to identify delirium that is most associated with poor long-term outcomes. Clearly, delirium includes impairments in both cognition and arousal in many cases.
While distinguishing an over-sedated patient from a delirious patient can be challenging, this distinction is in fact clinically relevant. Delirium lasting for 2-3 days or more has been associated with poorer outcomes than more transient episodes, which are often due to psychoactive medications. 32, 113 Sedation scales alone (such as the Richmond Agitation and Sedation Scale, RASS), 38, 114 which are neither sensitive nor specific for delirium, should not be used alone but rather in conjunction with tests of attention and cognition (in verbal patients) or other diagnostic evaluations. Moreover, while carrying its own prognostic risks, the etiology, pathophysiology, and management of over-sedation should be considered quite distinct from the management of delirium.
Are there pathophysiologic or prognostic differences in the forms of delirium or in specific
clinical manifestations? Delirium has two major psychomotor forms: hypoactive and hyperactive. Patients with acute alcohol withdrawal are more likely to present with the hyperactive form. The predominantly hypoactive form is more common in older patients, and has been generally associated with a worse prognosis. 52 While these two forms are distinctive clinically, patients can wax and wane between the two forms during the course of a day or the course of their delirium. EEG manifestations are not reliably different between the two forms. 115 Current delirium severity instruments (e.g., DRS98 and MDAS) tend to have more hyperactive symptoms represented in their summative scores than hypoactive symptoms, thus tending to weight hyperactive delirium as more severe. In addition, it is unclear whether different causal mechanisms can be separated by clinical signs and symptoms; that is, are there different, recognizable phenotypes of delirium well beyond the two forms described above? 116, 117 Do specific clinical manifestations, such as hallucinations, indicate a separate pathophysiology or prognosis? Clarification of these issues with improved delirium measurement methods and application of sophisticated neuroimaging and pathophysiologic approaches holds substantial ramifications for understanding both the phenomenology and treatment of delirium.
What are appropriate treatment strategies for delirium? Current clinical trials for delirium management have focused primarily on antipsychotic or sedating medications. While these treatments may reduce the agitation and behavioral symptoms associated with delirium, which are often vexing to healthcare professionals, there is no evidence that these treatments are effective for improving outcomes from delirium. Given the limitations of our measurement instruments, a distinct possibility is that these treatments may convert hyperactive to hypoactive delirium (which is then not measured), contributing to these poor outcomes. Increasing evidence suggests that these treatments may prolong the duration of delirium, prolong associated cognitive impairments, and worsen clinical outcomes. Thus, consideration of other approaches is critical at this juncture, including nonpharmacologic strategies, cognitive rehabilitation, drug reduction or drug-sparing approaches (i.e., substituting less toxic alternatives), and treatments targeted towards inflammation, neuroprotection, sleep enhancement (e.g., melatonin), and reduction of pain and stress including complementary and alternative medicine. Our current approaches for management of delirium must focus on treatments that enhance recovery, maximize functional status, and improve clinical outcomes.
Future Directions and Recommendations
While many knowledge gaps remain, the groundwork laid by the current evidence in delirium highlights a clear path to move forward. Table 7 outlines some of the research priorities in delirium research, and the concomitant public health priorities that will be needed to move the field ahead. Each research domain must be coupled with translation into practice and policy to impact on the problem of delirium. Important public health and policy priorities should include more logical coding and reimbursement strategies for delirium. Currently, there are at least 11 codes for delirium in ICD-9 CM and 23 codes in ICD-10, yet only about 3% of delirium cases are coded in medical records. 49 Without a more logical system to record delirium that is occurring in our healthcare systems, large-scale public health efforts will be severely limited. In addition, comprehensive efforts to educate clinicians and the public about delirium, including its importance, recognition, risk factors, prevention and management strategies, will be critical to change the current state of under-recognition and mismanagement. Delirium serves as a potent and well-recognized indicator of healthcare quality across many settings, and creating incentives for system-wide process improvement to address delirium will result in high quality geriatric care more generally. Given that delirium is highly multifactorial and linked to many other common geriatric syndromes (such as falls, pressure ulcers, functional decline, and incontinence), addressing delirium provides a highly practical and effective strategy to improve outcomes, decrease costs, and raise the quality of healthcare system-wide.
[Panel] Summary Messages for Clinicians
As the case demonstrates, delirium is easy to overlook without formal cognitive assessment. A brief cognitive examination would have assisted in identification of delirium, hastened appropriate management, and helped to reduce its associated adverse outcomes. In addition, seniors are often on multiple psychoactive medications which increase risk for delirium in the face of stressors such as acute infection. Falling and loss of appetite are often warning signs for delirium. Helpful take-home messages are summarized below (See:
www.hospitalelderlifeprogram.org):
1. Assess for delirium in all older hospitalized patients: use simple cognitive screening and the Confusion Assessment Method. Be sure to get the history or timecourse of any cognitive changes from an informed proxy.
2. Evaluating medications is a high-yield procedure (the medication list "biopsy"). Reduce psychoactive medications as a first step wherever possible.
3. Use nonpharmacologic approaches to manage sleep, anxiety, and agitation.
4. Reserve pharmacologic approaches for patients with severe agitation, which will result in interruption of essential medical therapies (e.g., intubation) or poses a danger for self-injury;
or for cases with severe, distressing psychotic symptoms (e.g., hallucinations, delusions).
5. Involve family members in care, particularly for reorientation and prevention of self-harm.
6. Avoid bedrest orders; encourage mobility and self-care.
7. Make sure that patients have their glasses, hearing aids, and dentures. Being able to see, hear, and eat are important in all healthcare settings.
8. Let patients know their schedule and keep them involved in their care. Communicate regularly with patients and their families.
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Non-Cardiac ---13% -50% Tables 4-5 for complete list of references and further details on all articles. All values in this table were derived from selected articles meeting the following criteria: sample size of 100 or more; satisfaction of STROBE criteria for setting, participants, measurement and statistical methods; and using a validated delirium instrument. An additional inclusion criterion for incidence studies was serial delirium assessments at no more than 3 day intervals by trained research staff or clinicians. † The sum of both prevalence and incidence yields the overall occurrence rates of delirium in each setting. ‡ Adjusted relative risks were derived from studies that provided adjustment for at least one covariable. • Reserve for patients with severe agitation, which will result in interruption of essential medical therapies (e.g., intubation) or severe psychotic symptoms • Start low doses and titrate until effect achieved; haloperidol 0.25-0.5 mgs. po/IM BID preferred; atypical antipsychotics close in effectiveness.
*BID=twice daily; CBC=complete blood count; IM=intramuscular; mgs=milligrams; po=by mouth; PRN=as needed medication. Table 8 for complete list of references. All studies included had modified Jadad quality scores of 4 or greater. C=control patients; CI=95% confidence interval; HR=hazard ratio; I=intervention patients; ICU=intensive care unit; LOS=hospital length of stay; NS=not significant; OR=odds ratio; P=prevention trial; RN=registered nurse; T=treatment trial. †The modified Jadad score (6 points) included: randomization or balanced allocation (1 point); description of method for balanced allocation (1); double blinding (1); description of double-blinding (1); description of withdrawals/dropouts (1); sample size ≥ 100 (1) * See Appendix Table 8 for complete list of references. All studies included had modified Jadad quality scores of 4 or greater. C=control patients; CI=95% confidence interval; HR=hazard ratio; I=intervention patients; ICU=intensive care unit; LOS=hospital length of stay; NS=not significant; OR=odds ratio; P=prevention trial; RN=registered nurse; T=treatment trial. †The modified Jadad score (6 points) included: randomization or balanced allocation (1 point); description of method for balanced allocation (1); double blinding (1); description of double-blinding (1); description of withdrawals/dropouts (1); sample size ≥ 100 (1) • 'Deliriomics' to identify biomarkers • Animal models for delirium
• Improve funding for delirium research overall • Encourage interdisciplinary scientists to address the topic Prevention and Treatment
• Evaluate long-term effects of nonpharmacologic prevention strategies • Trials of medication reduction: more prudent, individualized approaches to sedation, anesthesia, and analgesia • Combined approaches to management, such as music, massage, exercise, cognitive rehabilitation, and sleep enhancement
• Incentives for system-wide process and quality improvements in delirium detection, prevention and treatment • Provider education: delirium prevention and management approaches • Public education: avoid psychoactive drugs (including over-the-counter), limit alcohol use, encourage exercise, and enhance cognitive reserve
